IMMIX BIOPHARMA, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
IMMIX BIOPHARMA, INC. (IMMX) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $13.08 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-07
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was $13.08K, a 73.60% decline year-over-year.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was $45.48K, a 175.30% increase year-over-year.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was -$2.30K.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$2.57K, a 103.42% decline year-over-year.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $61.22K.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$135.72K, a 384.86% decline from fiscal 2023.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $47.65K.
- IMMIX BIOPHARMA, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$38.39K.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.08K 10-Q · filed 2026-08-07 | $58.56K 10-Q · filed 2026-08-07 | $56.26K derived: sum of 3 quarters · filed 2026-08-07 | $53.69K derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $45.48K 10-Q · filed 2026-05-07 | $43.17K derived: sum of 2 quarters · filed 2026-05-07 | $40.60K derived: sum of 3 quarters · filed 2026-05-07 | $90.17K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | -$2.30K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | -$4.87K derived: sum of 2 quarters · filed 2026-03-27 | $44.70K derived: sum of 3 quarters · filed 2026-08-07 | $61.22K 10-K/A · filed 2026-03-27 |
| 2025-09-30 | -$2.57K 10-Q · filed 2025-11-07 | $47.00K derived: sum of 2 quarters · filed 2026-08-07 | $63.52K 10-Q · filed 2025-11-07 | -$129.59K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $49.57K 10-Q · filed 2026-08-07 | $66.09K 10-Q · filed 2026-08-07 | -$127.02K derived: sum of 3 quarters · filed 2026-08-07 | -$51.94K derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $16.52K 10-Q · filed 2026-05-07 | -$176.59K derived: sum of 2 quarters · filed 2026-05-07 | -$101.51K derived: sum of 3 quarters · filed 2026-05-07 | -$74.15K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$193.11K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-03-27 | -$118.03K derived: sum of 2 quarters · filed 2026-03-27 | -$90.67K derived: sum of 3 quarters · filed 2026-03-27 | -$135.72K 10-K/A · filed 2026-03-27 |
| 2024-09-30 | $75.08K 10-Q · filed 2025-11-07 | $102.44K derived: sum of 2 quarters · filed 2025-11-07 | $57.38K 10-Q · filed 2025-11-07 | $145.32K derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $27.36K 10-Q · filed 2025-08-08 | -$17.69K 10-Q · filed 2025-08-08 | $70.24K derived: sum of 3 quarters · filed 2025-08-08 | $36.09K derived: sum of 4 quarters · filed 2025-08-08 |
| 2024-03-31 | -$45.05K 10-Q · filed 2025-05-08 | $42.88K derived: sum of 2 quarters · filed 2025-05-08 | $8.73K derived: sum of 3 quarters · filed 2025-05-08 | $7.07K derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $87.93K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $53.78K derived: sum of 2 quarters · filed 2025-03-25 | $52.12K derived: sum of 3 quarters · filed 2025-03-25 | $47.65K 10-K · filed 2025-03-25 |
| 2023-09-30 | -$34.15K 10-Q · filed 2024-11-12 | -$35.81K derived: sum of 2 quarters · filed 2024-11-12 | -$40.29K 10-Q · filed 2024-11-12 | -$15.32K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$1.67K 10-Q · filed 2024-08-12 | -$6.14K 10-Q · filed 2024-08-12 | $18.83K derived: sum of 3 quarters · filed 2024-08-12 | -$21.56K derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$4.47K 10-Q · filed 2024-05-09 | $20.49K derived: sum of 2 quarters · filed 2024-05-09 | -$19.90K derived: sum of 3 quarters · filed 2024-05-09 | -$58.45K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $24.97K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$15.42K derived: sum of 2 quarters · filed 2024-03-29 | -$53.97K derived: sum of 3 quarters · filed 2024-03-29 | -$38.39K 10-K · filed 2024-03-29 |
| 2022-09-30 | -$40.39K 10-Q · filed 2023-11-13 | -$78.94K derived: sum of 2 quarters · filed 2023-11-13 | -$63.35K 10-Q · filed 2023-11-13 | -$61.81K derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$38.55K 10-Q · filed 2023-08-11 | -$22.96K 10-Q · filed 2023-08-11 | -$21.43K derived: sum of 3 quarters · filed 2023-08-11 | -$24.95K derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $15.59K 10-Q · filed 2023-05-12 | $17.13K derived: sum of 2 quarters · filed 2023-05-12 | $13.61K derived: sum of 3 quarters · filed 2023-05-12 | $18.30K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $1.54K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$1.98K derived: sum of 2 quarters · filed 2023-03-27 | $2.72K derived: sum of 3 quarters · filed 2023-03-27 | -$6.45K 10-K · filed 2023-03-27 |
| 2021-09-30 | -$3.52K 10-Q · filed 2022-11-09 | $1.18K derived: sum of 2 quarters · filed 2022-11-09 | -$7.99K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $4.70K 10-Q · filed 2022-08-12 | -$4.47K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | -$9.17K 10-Q · filed 2022-05-13 | |||
| 2020-12-31 | $63.64K 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |